BridgeMD
New treatment option for Ischemic Stroke
Official title Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke
ClinicalTrials.gov ID: NCT06649240
What this study is testing
What is Statins and/or Ezetimibe?
Statins and/or Ezetimibe is an investigational medicine, being studied as a potential treatment for ischemic stroke.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Lipid-lowering therapy constitutes a cornerstone of secondary prevention in ischemic stroke; however, current stroke guidelines remain deficient in providing optimal target low-density lipoprotein (LDL)-cholesterol levels tailored to the stroke subtypes. Most clinical trials on LDL-cholesterol management have not differentiated between stroke subtypes or have primarily focused on large artery atherosclerosis (LAA) stroke, leaving a gap in evidence for managing LDL-cholesterol in other stroke subtypes, e.g., small vessel occlusion (SVO) stroke.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 19 and older
You may be able to join if
- Age 19 years or older
- Patients with objectively confirmed small vessel occlusive infarctions in the subcortical or brainstem regions, identified through neuroimaging (MRI...
- Patients with a history of symptomatic ischemic stroke caused by the lesion described in 2), occurring within 180 days prior to enrollment
- Patients or guardians who agree to the study protocol and sign with informed consent
You likely can't join if
- Patients requiring intensive LDL cholesterol management (LDL-C \<70 mg/dL) due to another condition, with LDL cholesterol targets specified in the...
- Patients contraindicated for statin use (e.g., active liver disease, serum transaminase levels elevated more than three times the normal limit...
- Women who are pregnant, breastfeeding, or intending to become pregnant during the study period
- Deemed unsuitable for participation in the study for more than four years, as per the investigators' discretion
The study team makes the final eligibility decision.
Where it's taking place
- Ansan, South Korea
- Anyang, South Korea
- Busan, South Korea
- Changwon, South Korea
- Cheongju-si, South Korea
- Chuncheon, South Korea
- Daegu, South Korea
- Daejeon, South Korea
- Goyang, South Korea
- Guri-si, South Korea
- Gwangju, South Korea
- Gwangmyeong, South Korea
- Hwaseong, South Korea
- Iksan, South Korea
- Incheon, South Korea
- Jeju City, South Korea
- Seongnam, South Korea
- Seoul, South Korea
- Yongin, South Korea
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 19 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Ansan, South Korea; Anyang, South Korea; Busan, South Korea; Changwon, South Korea; Cheongju-si, South Korea; Chuncheon, South Korea and 13 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.